Gilead Sciences' Revenue and Earnings Slip in Second Quarter

On the surface, Gilead Sciences' (NASDAQ:GILD) second quarter was ugly. Revenue and earnings both declined year over year.

Sales decreased 10% in the second quarter to $5.1 billion, with Gilead's hepatitis C drug franchise contributing to most of the decline, down a whopping 47% year over year.